Insider Trading March 18, 2026

Exzeo CEO Paresh Patel Buys $63,960 of Stock Amid Year-to-Date Decline

Two small open-market purchases boost Patel’s stake as company reports in-line Q4 and 2025 results

By Nina Shah XZO
Exzeo CEO Paresh Patel Buys $63,960 of Stock Amid Year-to-Date Decline
XZO

Exzeo Group Chief Executive Officer Paresh Patel acquired 4,000 shares of company common stock in two purchases on March 17 and March 18, 2026, totaling $63,960. The buys come while the shares trade well below their 52-week high and after Exzeo reported fourth-quarter and full-year 2025 results that met analysts’ expectations.

Key Points

  • CEO Paresh Patel purchased 4,000 shares in two open-market transactions on March 17 and March 18, 2026, spending a total of $63,960.
  • After these purchases Patel directly owns 1,576,013 shares and holds options to buy 5,000,000 shares at an exercise price of $23; the options were granted on October 1, 2021, and began vesting on October 1, 2022.
  • Exzeo reported fourth-quarter and full-year 2025 results with diluted EPS of $0.25 and quarterly revenue of $53.32 million, meeting analysts’ forecasts; the stock has fallen 34% year-to-date and trades at $15.16 versus a 52-week high of $24.60, while analyst targets range from $25 to $27.

Exzeo Group, Inc. reported insider purchases by Chief Executive Officer Paresh Patel in filings with the Securities and Exchange Commission. The Form 4 discloses two separate transactions executed on March 17 and March 18, 2026, in which Patel purchased a total of 4,000 shares of Exzeo common stock for $63,960.

Per the filing, Patel acquired 2,000 shares on March 17 at $15.68 per share, and an additional 2,000 shares on March 18 at $16.30 per share. Following these transactions, Patel’s direct holdings of Exzeo common stock total 1,576,013 shares.

The Form 4 also details long-term incentive instruments held by the CEO. Patel holds options to purchase 5,000,000 shares of Exzeo common stock with an exercise price of $23 per share. Those options were granted on October 1, 2021, and the vesting schedule began with installments starting on October 1, 2022.

The purchases occurred against a backdrop of notable share-price movement year-to-date. The stock has fallen 34% so far this year and was trading at $15.16, well below its 52-week high of $24.60. Despite that decline, analysts covering the company have set price targets in the $25 to $27 range.

Exzeo recently released its fourth-quarter and full-year results for 2025, reporting diluted earnings per share of $0.25 and quarterly revenue of $53.32 million, results that matched analysts’ forecasts. The earnings release prompted a positive reaction in aftermarket trading, according to the filing and related market commentary.

No recent announcements regarding mergers or acquisitions were recorded in conjunction with the earnings release, and analyst firms had not issued fresh upgrades or downgrades following the report. The mixed signals of in-line financial performance, a substantial year-to-date share-price decline, and continued analyst price targets framed the trading context for the insider purchases.

For investors and market observers seeking supplemental data, the filing referenced resources that offer additional analysis and metrics specific to XZO, including six additional ProTips related to valuation and performance.

Patel’s purchases represent incremental open-market acquisitions by a senior executive, and the Form 4 provides a detailed snapshot of ownership and option holdings at the senior management level. The filings and recent earnings release together underline current market perceptions and the information available to shareholders and analysts evaluating Exzeo’s near-term outlook.

Risks

  • Significant year-to-date share-price decline of 34% may reflect market concerns and represents downside risk for equity investors and market participants.
  • Outstanding options have an exercise price of $23, which is above the current trading price of $15.16, creating uncertainty about potential option exercise timing and dilution effects for shareholders.
  • No recent analyst upgrades or downgrades and absence of announced mergers or acquisitions mean limited near-term changes to consensus views; this creates uncertainty for investors and equity market participants.

More from Insider Trading

Williams-Sonoma CEO Disposes of $3.6M in Stock; Holdings Remain Substantial Mar 18, 2026 MediaAlpha CEO Sells 4,000 Shares to Cover RSU Taxes; Q4 Revenue Slightly Misses Estimates Mar 18, 2026 FormFactor CEO Disposes of $973k in Stock as Company Posts Q4 Beat Mar 18, 2026 Recursion CFO Sells $26,970 in Shares as Stock Hovers Near 52-Week Low Mar 18, 2026 Limbach CFO Executes $778,550 10b5-1 Stock Sale Mar 18, 2026